Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Letrozole Clear all
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

NCT00134680
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Letrozole, Trastuzumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 20, 2026, 2:11 PM EDT
Terminated Phase 1 Interventional

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

NCT01208441
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
letrozole, gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, breast biopsy, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

NCT00338728
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Imatinib Mesylate, Letrozole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

NCT00634634
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sorafenib, Letrozole
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 20, 2026, 2:11 PM EDT
Not listed No phase listed Observational

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

NCT00897065
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique
Genetic · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Female only
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 20, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

NCT00999804
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib, Letrozole, Trastuzumab
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Letrozole and Misoprostol for Early Pregnancy Loss Management

NCT06452719
View directory record Official record
Conditions
Early Pregnancy Loss, Miscarriage in First Trimester, Miscarriage
Interventions
Letrozole, Misoprostol
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Early Phase 1 Interventional

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

NCT04049227
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma
Interventions
Abemaciclib, Letrozole, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

NCT00248170
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Anastrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
33 Years to 96 Years · Female only
Enrollment
4,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

NCT04002141
View directory record Official record
Conditions
Endometriosis, Ovarian Hyperstimulation
Interventions
Placebo oral tablet, Letrozole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 20, 2026, 2:11 PM EDT
Recruiting Early Phase 1 Interventional

Study of Letrozole in Recurrent Gliomas

NCT03122197
View directory record Official record
Conditions
Brain Tumor
Interventions
Letrozole Oral Tablet, Temozolomide
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 1 Interventional

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

NCT02152943
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 20, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648
View directory record Official record
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

NCT01958021
View directory record Official record
Conditions
Advanced, Metastatic Breast Cancer
Interventions
Ribociclib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
73
States / cities
Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 20, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

NCT02907918
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Breast Carcinoma
Interventions
Palbociclib, Letrozole, Trastuzumab, Goserelin, Breast surgery, Research tumor biopsy, Research bone marrow (OPTIONAL), Research blood sample, Research blood for germline DNA, Blood for detection of circulating tumor cells
Drug · Biological · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • St Louis, Missouri • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

NCT00728949
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Hepatic Safety of EGCG

NCT04177693
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Epigallocatechin gallate (EGCG), Clomiphene Citrate, Letrozole
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 20, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

Letrozole in Preventing Breast Cancer in Postmenopausal Women

NCT00090857
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
35 Years to 120 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 20, 2026, 2:11 PM EDT
Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 20, 2026, 2:11 PM EDT
Active, not recruiting Phase 1 Interventional

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

NCT03006172
View directory record Official record
Conditions
Breast Cancer, Solid Tumor
Interventions
Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 20, 2026, 2:11 PM EDT
Recruiting Phase 3 Interventional

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
85
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00549822
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 20, 2026, 2:11 PM EDT